hVIVO Regulatory News (HVO)

For immediate release 07.00: 23 August 2013

RETROSCREEN VIROLOGY GROUP PLC

("Retroscreen" or the "Company")

CONTRACT WIN

Retroscreen Virology Group plc (AIM: RVG), the viral challenge and "virometrics" specialist, is pleased to announce the signing of a new Viral Challenge Model ("VCM") contract with a global pharmaceutical company for the provision of a human respiratory syncytial virus (RSV) challenge study, with the contract valued at £4.7m.

Kym Denny, Chief Executive Officer, commented, "We are delighted with this new award, and look forward to delivering another reliable and high quality piece of clinical research. With investment into new drugs and vaccines continuing apace, and with the backdrop of the pharma industry's lengthy timescales and high costs of research and development, more biotechnology and pharmaceutical companies are increasingly recognising Retroscreen's VCM as an attractive solution for faster, more reliable and highly controlled research programmes with earlier endpoint analysis and decision-making."

For further information please contact:

Retroscreen Virology Group plc +44 207 756 1300

Kym Denny (CEO)

Graham Yeatman (FD)

Numis Securities Limited +44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Michael Burke (Corporate Broking)